Peg, VicenteLópez-García, María ÁngelesComerma Blesa, Laura, 1983-Peiró, GloriaGarcía-Caballero, TomásConcha López, ÁngelSuárez-Gauthier, AnaRuiz, IruneRojo, Federico2021-07-132021-07-132021Peg V, López-García MÁ, Comerma L, Peiró G, García-Caballero T, López ÁC, et al. PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion. Future Oncol. 2021 Apr; 17(10): 1209-18. DOI: 10.2217/fon-2020-11001479-6694http://hdl.handle.net/10230/48161Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC.application/pdfengThis work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/articlehttp://dx.doi.org/10.2217/fon-2020-1100PD-L1AntibodyBreast cancerDiagnosisImmunohistochemistryImmunotherapyinfo:eu-repo/semantics/openAccess